Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Keros TherapeuticsKROS -1.09%30 EV-to-EBIT is 0.61 as of Jul. 30, 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 381 Biotechnology companies, Keros Therapeutics ranks better than 80.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Keros Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-47.33 Mil.
Keros Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-110.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics EV-to-EBIT Related Terms
Keros Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Keros Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Keros Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's EV-to-EBIT falls into.
Keros Therapeutics's current Enterprise Value is $-67.86 Mil.
Keros Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-110.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (KROS) has a EV-to-EBIT of 0.61 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #73 out of 381 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Keros Therapeutics' EV-to-EBIT too high?
Keros Therapeutics' current EV-to-EBIT is 0.61. The Biotechnology industry median EV-to-EBIT is 12.81. Keros Therapeutics' value of 0.61 is 95.2% below this industry median. Based on the distribution chart, Keros Therapeutics ranks #73 out of 381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' EV-to-EBIT compare to RNA and NBP?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #73 out of 381 companies for EV-to-EBIT. This places Keros Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.81. Keros Therapeutics' value of 0.61 is 95.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.81, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keros Therapeutics's current EV-to-EBIT of 0.61 is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Keros Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current EV-to-EBIT is 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current EV-to-EBIT of 0.61. The current EV-to-EBIT is 0.61 and 95.2% below the Biotechnology industry median of 12.81. Keros Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current EV-to-EBIT is 0.61 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score
Get the complete analysis for KROS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
